New ACE data presented at the 2017 IDF Congress


A total of 7534 delegates from 182 countries attended the 2017 IDF Congress in Abu Dhabi.
On Wednesday 6th December, Professor Rury Holman gave an invited talk in the "Latest Cardiovascular Clinical Trials" symposium. He reprised the recently published results of the Acarbose Cardiovascular (ACE) trial, and showed new data highlighting the significantly greater proportion of participants with impaired glucose tolerance allocated to acarbose who became normoglycaemic, compared with those allocated to placebo.

[IDF Congress programme available here]